(0.33%) 5 116.91 points
(0.30%) 38 355 points
(0.38%) 15 988 points
(-0.87%) $83.12
(5.77%) $2.03
(0.46%) $2 357.90
(0.47%) $27.67
(3.91%) $958.20
(-0.22%) $0.933
(-0.40%) $10.98
(-0.54%) $0.796
(1.66%) $93.40
@ $12.36
発行日: 14 2月 2024 @ 23:30
リターン: -6.80%
前回のシグナル: 2月 13 - 05:00
前回のシグナル:
リターン: -1.98 %
Live Chart Being Loaded With Signals
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation...
Stats | |
---|---|
本日の出来高 | 43 092.00 |
平均出来高 | 204 745 |
時価総額 | 370.60M |
EPS | $0 ( 2024-04-25 ) |
次の収益日 | ( $0.0300 ) 2024-05-16 |
Last Dividend | $0.100 ( 2022-01-05 ) |
Next Dividend | $0 ( N/A ) |
P/E | 42.67 |
ATR14 | $0.0260 (0.23%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-25 | Moorhead Daniel J | Sell | 6 084 | Common Stock |
2024-03-25 | Lucsok Anna | Sell | 7 672 | Common Stock |
2024-03-25 | Sandgaard Thomas | Sell | 2 268 | Common Stock |
2024-03-05 | Moorhead Daniel J | Buy | 5 000 | Common Stock (Restricted Stock Award) |
2024-01-27 | Lucsok Anna | Buy | 5 000 | Common Stock (Restricted Stock Award) |
INSIDER POWER |
---|
-38.23 |
Last 100 transactions |
Buy: 368 705 | Sell: 936 982 |
ボリューム 相関
Zynex Inc 相関
10 最も負の相関 | |
---|---|
APOP | -0.971 |
RMRM | -0.939 |
MAGS | -0.936 |
TDAC | -0.897 |
CMLF | -0.868 |
SVOK | -0.836 |
EMBCV | -0.824 |
TLGT | -0.823 |
SPRT | -0.82 |
TALS | -0.82 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Zynex Inc 相関 - 通貨/商品
Zynex Inc 財務諸表
Annual | 2023 |
収益: | $184.32M |
総利益: | $145.96M (79.19 %) |
EPS: | $0.270 |
FY | 2023 |
収益: | $184.32M |
総利益: | $145.96M (79.19 %) |
EPS: | $0.270 |
FY | 2022 |
収益: | $158.17M |
総利益: | $126.16M (79.77 %) |
EPS: | $0.440 |
FY | 2021 |
収益: | $130.30M |
総利益: | $102.98M (79.03 %) |
EPS: | $0.450 |
Financial Reports:
No articles found.
Zynex Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.136 | 2014-06-17 |
Last Dividend | $0.100 | 2022-01-05 |
Next Dividend | $0 | N/A |
Payout Date | 2022-01-21 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | $0.300 | -- |
Avg. Dividend % Per Year | 0.21% | -- |
Score | 2.67 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.49 | |
Div. Directional Score | 7.84 | -- |
Year | Amount | Yield |
---|---|---|
2014 | $0.136 | 42.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0.0636 | 2.14% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0.100 | 1.07% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0528 | 1.500 | 8.94 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0690 | 1.200 | 7.70 | 9.24 | [0 - 0.3] |
returnOnEquityTTM | 0.168 | 1.500 | 9.24 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.000308 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 4.74 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.85 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.41 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.436 | -1.500 | 2.73 | -4.10 | [0 - 0.6] |
interestCoverageTTM | 11.13 | 1.000 | 6.99 | 6.99 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.531 | 2.00 | 9.82 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.495 | 2.00 | 9.75 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.334 | -1.500 | 4.66 | -7.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.792 | 1.000 | 0.136 | 0.136 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0661 | 1.000 | -0.678 | -0.678 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.290 | 1.000 | 9.50 | 9.50 | [0.2 - 2] |
assetTurnoverTTM | 1.307 | 0.800 | 4.62 | 3.70 | [0.5 - 2] |
Total Score | 11.20 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 38.70 | 1.000 | 6.19 | 0 | [1 - 100] |
returnOnEquityTTM | 0.168 | 2.50 | 9.51 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.495 | 2.00 | 9.84 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.531 | 2.00 | 9.82 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.000308 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0.378 | 1.500 | -0.813 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0967 | 1.000 | -0.0814 | 0 | [0.1 - 0.5] |
Total Score | 4.49 |
Zynex Inc
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。